Discover our value-focused philosophy and unique venture ecosystem.
The LvlUp Ventures First Check Fund. 1,000 investments in 2026.
Discover LvlUp's unique venture debt / non-dilutive financing fund for B2B startups.
See how we're powering non-dilutive growth for pre-seed to growth-stage startups.
Learn how we're backing the next generation of e-commerce ecosystem technology.
A boutique program for founders with hands-on-support.
See how we're scaling the future of CPG brands.
Enabling non-dilutive growth for CPG startups.
A high-touch accelerator for founders building scalable consumer brands.
High-conviction capital. Strategic scale.
Supporting brick-and-mortar and service businesses with equity capital and financing.
Supporting brick-and-mortar and services businesses with non-dilutive growth.
Who we are, how we invest and how LvlUp has grown since 2023.
Meet our core, associate, and extended team powering the ecosystem.
Read articles from the LvlUp team, our VCs in residence, and guest contributors.
Learn more about our process and unique offerings for LPs.
Bringing LvlUp's capital, network, and operating infrastructure to Europe, from Paris.
Bringing LvlUp's capital, network, and operating infrastructure to the Middle East, from Dubai.
LvlUp Ventures backs founders from first check to late stage.
Apply for fundingMelliCell is a biotechnology company developing fat-targeted therapeutics for obesity and related chronic diseases. Powered by its proprietary M3 technology, it generates mature human adipose tissue in vitro to illuminate adipocyte biology and enable drug discovery, tissue engineering, and regenerative applications. The pipeline includes MCL5008, an oral, once-daily obesity therapy candidate designed to eliminate obesity without muscle loss, taking a fat-cell-directed approach distinct from GLP-1 drugs.
